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Sir,
The article of Nakajima et al (2003) in the Journal addresses a
problem of major public health importance, concluding that
screening programme with immunochemical faecal occult blood
test (FOBT) can be effective for prevention of advanced colorectal
cancer. However, the screening method applied in their case–
control study (i.e. the immunochemical haemagglutination method
described by Saito et al (1995) may direct the attention to the
rather controversial area of which is the optimal screening tool, if
any, for early detection of colorectal cancer and its precursors.
Recently, the scientific and clinical evidences for the use of the
available colorectal cancer-screening tests were critically assessed
(Walsh and Terdiman, 2003a,b). Supported by a large body of
direct and indirect evidence, those review articles concluded
recommending that all asymptomatic men and women over 50
years of age and older should undergo screening; however, it
stated, ‘at present, the available evidence does not support
choosing any test over the others’. In the same time, after having
reviewed the available evidence, a special advisory group
appointed by the American Cancer Society highlighted immuno-
logical stool testing as the only exception from its general
conclusion that this time there is insufficient evidence to
recommend the other emerging technologies for routine colorectal
cancer screening (Levin et al, 2003).
Since the effectiveness of FOBT has been established by
randomised controlled trials (Mandel et al, 1993; Mendel et al,
1999; Kronborg et al, 1996; Hardcastle et al, 1996), several tests
based on peroxidase activity and guaiac-type reagents for colour
reaction are most widely used on a public health scale, being
noninvasive, simple and cheap methods, However, these reagents
are not human-specific, because they may give positive reaction
even with the peroxidase of several food stuffs, both of plant and
animal origin (Cole and Young, 1999). These shortcomings result
in an unacceptably high false positive rate.
To eliminate these shortcomings, a number of combined methods
consisting of a guaiac test and an immunochemical test have been
developed. In addition to the increased specificity, the immuno-
chemical FOBTs have the advantage of not requiring dietary or drug
restrictions, therefore are more patient-friendly, and more suitable
for mass application. In recent years, several such immunological
techniques have developed (Otto ´ and Eckhardt, 2000).
However, several problems may reduce the efficiency of these
methods (St John et al, 1993; Otto ´ and Eckhardt, 2000). Most of
these immunological techniques are usually limited to the
demonstration of haemoglobin in the faeces. For example,
depending on the site of bleeding, a certain degradation of haemo-
globin may take place, or, faecal haemoglobin may become
irreversibly bound to special components of the faeces. To eliminate
these potential sources of error, some investigators have suggested
the demonstration of additional proteins, more stable in the faeces
than haemoglobin, as possible new indicators of intestinal bleeding.
We ourselves have developed a combined electrophoretic–
immunoprecipitation technique of high sensitivity (2mgml
1),
suitable for simultaneous demonstration of two blood proteins,
that is, haemoglobin and albumin, in the faecal sample (Otto ´ and
Ne ´meth, 1993). The technique is simple, inexpensive and suitable
for the reliable detection of occult blood. The parallel demonstra-
tion of the two proteins significantly enhanced the detectability of
symptomless colorectal cancer (Otto ´ and Ne ´met, 1996). Further-
more, using immune sera raised against native haemoglobin and
its fragments, as a differential diagnostic method, our technique is
suitable for parallel demonstration of haemoglobin and its
fragments; in this way, the origin of the bleeding can be localised
(Otto ´ et al, 1995).
The modified two-phase (guaiac-type and immunochemical)
faecal occult blood test (FECA-TEST) was used (without diet) as a
screening tool in a pilot population-screening project for early
detection of colorectal cancer. The project was carried out in
1997–1998 in a well-defined administrative area of the Capital,
Budapest, Hungary (where – like in many other developed
countries – colorectal cancer is the second leading cause of cancer
death; therefore, screening for colorectal cancer is a major public
health concern) with support from the World Bank ‘Close the gap’
public health programme. The purpose of the project was to
demonstrate the feasibility and validity of the test is screening
context, in addition to social acceptance and impact on early cure.
In total, 21945 persons of the target population received the
sample collecting containers, distributed by the family physicians,
and 6805 persons had returned it, thus the compliance rate was
31%. A total of 292 samples were technically unsatisfactory. The
mean age of those tested was 64 years (49–86); 6513 samples were
analysed at the Central Clinical Laboratory, National Institute of
Oncology (NIO), Budapest. The very sensitive colour reaction was
positive in 1892 cases (29% of all tested); in the second phase, the
immunochemical Hgb and Alb reactions were positive (5.8% of all
tests performed). The test-positive cases were referred for
colonoscopic assessment to the NIO. Colonoscopy was performed
on 243 persons (65% of those referred; the rest was lost for the
follow-up). Colorectal cancer was detected and histologically
confirmed in 12 cases (5% of all test positives); six out of 12
cancer cases proved to be in early stage (Dukes A). In additional 59 Published online 13 April 2004
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up period, seven cancer cases were diagnosed among those test-
positive cases who rejected the endoscopic assessment. The
parallel demonstration of the two proteins significantly enhanced
the detectability of colorectal cancer.
We are convinced that, at present, regular screening of
population at average risk, using the combined immunological
FOBT as screening tool, is the most promising way of reducing the
colorectal cancer burden, one of the leading causes of cancer death
in most of the developed countries worldwide.
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